Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 8:50 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 46 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Fungemia Clear all
Recruiting Phase 3 Interventional

A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis.

NCT05421858
View directory record Official record
Conditions
Candidemia, Candidiasis, Invasive
Interventions
Fosmanogepix, Caspofungin, Fluconazole, Placebo
Drug
Lead sponsor
Basilea Pharmaceutica
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
23
States / cities
Birmingham, Alabama • Duarte, California • Los Angeles, California + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2026 · Synced Oct 20, 2026, 8:50 AM EDT
Completed Phase 3 Interventional Results available

Isavuconazole (BAL8557) in the Treatment of Candidemia and Other Invasive Candida Infections

NCT00413218
View directory record Official record
Conditions
Candidiasis, Invasive, Candidemia, Mycoses
Interventions
Isavuconazole, Caspofungin, Voriconazole
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
18 Years and older
Enrollment
450 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
18
States / cities
Birmingham, Alabama • Palm Desert, California • Sacramento, California + 15 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Oct 20, 2026, 8:50 AM EDT
Completed No phase listed Observational

Voriconazole as Prophylaxis for Liver Transplant Recipients

NCT00177788
View directory record Official record
Conditions
Fungemia, Mycoses
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 16, 2012 · Synced Oct 20, 2026, 8:50 AM EDT
Completed Phase 3 Interventional

Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation

NCT04368559
View directory record Official record
Conditions
Candidemia, Mycoses, Fungal Infection, Fungemia, Invasive Candidiasis, Pneumocystis, Mold Infection, Invasive Fungal Disease, Prophylaxis of Invasive Fungal Infections, Aspergillus
Interventions
Rezafungin for Injection, Posaconazole, Fluconazole, Trimethoprim-sulfamethoxazole (TMP/SMX), Intravenous Placebo, Oral Placebo
Drug
Lead sponsor
Mundipharma Research Limited
Industry
Eligibility
18 Years and older
Enrollment
602 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
18
States / cities
Birmingham, Alabama • Los Angeles, California • Stanford, California + 13 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2026 · Synced Oct 20, 2026, 8:50 AM EDT
Completed Not applicable Interventional

Safety and Efficacy of Veronate® Versus Placebo in Preventing Nosocomial Staphylococcal Sepsis in Premature Infants

NCT00113191
View directory record Official record
Conditions
Nosocomial Infections, Sepsis, Staphylococcal Infections, Candidemia
Interventions
Veronate
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
3 Days to 5 Days
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
85
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 71 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2012 · Synced Oct 20, 2026, 8:50 AM EDT
Completed No phase listed Observational

The Impact of Chlorhexidine-Based Bathing on Nosocomial Infections

NCT00448942
View directory record Official record
Conditions
Nosocomial Bacteremia, Nosocomial Fungemia, MRSA Colonization, MRSA Infection, VRE Colonization, VRE Infection
Interventions
Daily bathing with Chlorhexidine based product
Behavioral
Lead sponsor
Hunter Holmes Mcguire Veteran Affairs Medical Center
Federal
Eligibility
18 Years and older
Enrollment
5,300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
4
States / cities
Baltimore, Maryland • St Louis, Missouri • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2007 · Synced Oct 20, 2026, 8:50 AM EDT
Completed Not applicable Interventional Results available

Rapid Identification and Susceptibility Testing of Pathogens From Blood Cultures

NCT01898208
View directory record Official record
Conditions
Bacteremia, Fungemia, Bloodstream Infection
Interventions
FilmArray testing, Antimicrobial Stewardship, Bacterial culture, Susceptibility testing
Device · Behavioral · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
Up to 99 Years
Enrollment
743 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 15, 2016 · Synced Oct 20, 2026, 8:50 AM EDT
Completed Phase 3 Interventional

The Safety and Efficacy of Anidulafungin Versus Comparator in Patients With Candidemia and Invasive Candidiasis

NCT00056368
View directory record Official record
Conditions
Candidiasis
Interventions
Anidulafungin, Fluconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
16 Years and older
Enrollment
256 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
King of Prussia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 21, 2008 · Synced Oct 20, 2026, 8:50 AM EDT
Completed Phase 3 Interventional Results available

Study To Assess Pharmacokinetics, Safety & Efficacy of Anidulafungin When Treating Children With Invasive Candidiasis

NCT00761267
View directory record Official record
Conditions
Candidemia
Interventions
Anidulafungin, Fluconazole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
1 Month to 17 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
24
States / cities
Long Beach, California • Los Angeles, California • Oakland, California + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2019 · Synced Oct 20, 2026, 8:50 AM EDT
Not listed No phase listed Observational

Assessment of Assay for Rapid Identification of Bloodstream Infections From Whole Blood

NCT04147975
View directory record Official record
Conditions
Bacteremia, Candidemia
Interventions
RaPID/BSI Test
Diagnostic Test
Lead sponsor
HelixBind, Inc.
Industry
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Marlborough, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 1, 2019 · Synced Oct 20, 2026, 8:50 AM EDT
Terminated Phase 1 Interventional

Micafungin Lock Therapy

NCT00809887
View directory record Official record
Conditions
Catheter-Related Fungal Infections
Interventions
Micafungin lock therapy
Drug
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
6 Months to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Dec 17, 2008 · Synced Oct 20, 2026, 8:50 AM EDT
Completed Phase 1 Interventional

Study of Mycamine® in Children With Fungal Infections to Evaluate Safety and Blood Levels of the Drug

NCT00608335
View directory record Official record
Conditions
Oropharyngeal Candidiasis, Candidemia, Invasive Candidiasis, Esophageal Candidiasis
Interventions
Micafungin
Drug
Lead sponsor
Astellas Pharma Inc
Industry
Eligibility
2 Years to 16 Years
Enrollment
84 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
7
States / cities
Los Angeles, California • Orange, California • Kansas City, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Oct 20, 2026, 8:50 AM EDT
Completed Phase 3 Interventional Results available

Open-Label Study to Evaluate the Efficacy and Safety of Oral Ibrexafungerp (SCY-078) in Patients With Candidiasis Caused by Candida Auris (CARES)

NCT03363841
View directory record Official record
Conditions
Candidiasis, Invasive, Candidemia
Interventions
SCY-078
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Jersey City, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 3, 2024 · Synced Oct 20, 2026, 8:50 AM EDT
Completed Phase 3 Interventional

Voriconazole to Treat Fungal Infections

NCT00001940
View directory record Official record
Conditions
Mycoses
Interventions
Voriconazole
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 20, 2026, 8:50 AM EDT
Completed Phase 3 Interventional

Comparing the Effectiveness of Fluconazole and a New Medicine (FK463) in Preventing Fungal Infections in Bone Marrow Transplant Patients

NCT00001937
View directory record Official record
Conditions
Aspergillosis, Candidiasis, Fungemia, Mycoses
Interventions
FK463, Fluconazole
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2000
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 20, 2026, 8:50 AM EDT
Completed Phase 2 Interventional

Safety and Efficacy of Interferon-Gamma 1b in Patients With Candidemia

NCT04979052
View directory record Official record
Conditions
Candidemia
Interventions
Interferon Gamma-1B
Drug
Lead sponsor
Radboud University Medical Center
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Jun 22, 2026 · Synced Oct 20, 2026, 8:50 AM EDT
Completed Phase 2 Interventional Results available

CD101 Compared to Caspofungin Followed by Oral Step Down in Subjects With Candidemia and/or Invasive Candidiasis-Bridging Extension

NCT02734862
View directory record Official record
Conditions
Candidemia, Mycoses, Fungal Infection, Fungemia, Invasive Candidiasis
Interventions
CD101, Caspofungin, Fluconazole, intravenous placebo, oral placebo
Drug
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
16
States / cities
Birmingham, Alabama • Davis, California • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Oct 20, 2026, 8:50 AM EDT
Completed Not applicable Interventional Results available

β-D-Glucan (BDG) Surveillance With Preemptive Anidulafungin vs. Standard Care for Invasive Candidiasis in Surgical Intensive Care Unit (SICU) Patients

NCT00672841
View directory record Official record
Conditions
Invasive Candidiasis
Interventions
Preemptive Therapy with Anidulafungin, Empiric antifungal therapy based on physician discretion.
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 6, 2015 · Synced Oct 20, 2026, 8:50 AM EDT
Completed Phase 4 Interventional Results available

Study Will Evaluate The Safety And Efficacy Of Anidulafungin In Patients With Candidemia Or Invasive Candidiasis

NCT00496197
View directory record Official record
Conditions
Candidiasis
Interventions
Eraxis (anidulafungin), Diflucan (fluconazole), Vfend (voriconazole)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
39
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Los Angeles, California + 25 more
Source: ClinicalTrials.gov public record
Updated Oct 3, 2011 · Synced Oct 20, 2026, 8:50 AM EDT
Completed Phase 1 Interventional

Pharmacokinetics (PK) Study of a Fluconazole Loading Dose in Infants and Toddlers

NCT00797420
View directory record Official record
Conditions
Candidiasis
Interventions
Fluconazole Loading Dose, Fluconazole Loading Dose & High Dose
Drug
Lead sponsor
Daniel Benjamin
Other
Eligibility
48 Hours to 2 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 5, 2018 · Synced Oct 20, 2026, 8:50 AM EDT
Completed Phase 2 Interventional

The Safety and Effectiveness of Intravenous Anidulafungin as a Treatment for Patients With Invasive Candidiasis.

NCT00037219
View directory record Official record
Conditions
Candidiasis
Interventions
Anidulafungin, VER002
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2002
U.S. locations
1
States / cities
King of Prussia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 21, 2008 · Synced Oct 20, 2026, 8:50 AM EDT
Completed No phase listed Observational

Detecting Infections Rapidly and Easily for Candidemia Trial (DIRECT)

NCT01525095
View directory record Official record
Conditions
Candidemia
Interventions
Not listed
Lead sponsor
T2 Biosystems
Industry
Eligibility
18 Years to 95 Years
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
5
States / cities
Birmingham, Alabama • San Francisco, California • Lexington, Kentucky + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2014 · Synced Oct 20, 2026, 8:50 AM EDT
Completed No phase listed Observational

Serial Therapeutic and Antifungal Monitoring Protocol

NCT02163889
View directory record Official record
Conditions
Candidemia
Interventions
Not listed
Lead sponsor
T2 Biosystems
Industry
Eligibility
18 Years to 95 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
3
States / cities
Birmingham, Alabama • Pittsburgh, Pennsylvania • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Aug 20, 2018 · Synced Oct 20, 2026, 8:50 AM EDT
Terminated Phase 3 Interventional Results available

A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole

NCT05178862
View directory record Official record
Conditions
Candidiasis, Invasive, Candidemia
Interventions
SCY-078, Fluconazole, Echinocandin
Drug
Lead sponsor
Scynexis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
26
States / cities
Birmingham, Alabama • Tucson, Arizona • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 20, 2026, 8:50 AM EDT